The stock of Atara Biotherapeutics Inc. (NASDAQ:ATRA) increased by $0.09 on Monday to finish at $4.91, up 1.87 percent. The last five days have seen an average of 1,748,600 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$10.85. The average number of shares traded over the last 20 days was 1,758,550, while the average volume over the last 50 days totaled 2,854,860.
ATRA stock appreciated 5.59% since last month. On 08/29/22, the company’s shares reached a one-month low of $3.86. The stock touched a high of $20.04 on 01/03/22, after rallying from a low of $2.83 in 52 weeks. The price of ATRA stock has declined by -68.85% or -$10.85 this year, reaching a new high 1 time. Still, the stock price is down -75.50% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
There have been 28 days since Atara Biotherapeutics Inc. (ATRA) last reported insider trading activity on Aug 16. On Aug 16, President and CEO Touchon Pascal sold 14,806 shares at $5.04 each. This transaction resulted in the insider making $74,548. On Aug 16, Dupont Jakob sold 4,124 shares at a price of US$5.03. After the transaction, the insider now owns 158,882 shares. SVP, GC & Secretary Murugan Amar had earlier sold 3,430 shares on Aug 16 for $5.03 a share. The transaction was completed for $17,269.
Beta for the stock is 0.95. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 6.36, the price-to-book (PB) ratio of 1.94.
For the three months ended June 29, Atara Biotherapeutics Inc.’s quick ratio was 5.30, while its current ratio was 5.30, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $360.8 million and revenue of $20.34 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ATRA’s return on assets (ROA) during the last 12 months has been -56.60%. There was a -121.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -92.40%.
According to Atara Biotherapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $260.62 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $51.58 million, while revenues rose by 92.5% to $7.31 million. It was predicted that Atara Biotherapeutics Inc.’s quarterly earnings would be $0.18, but it ended up being -$0.93, beating the consensus by 119.40%. EBITDA was -$30.38 million for the quarter. At the end of Atara Biotherapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 178.64 million, while its total debt was $74.67 million. Equity owned by shareholders amounts to $94.36 million.
Here’s a quick look at Atara Biotherapeutics Inc.’s (ATRA) price momentum from a technical perspective. As of 12 September, the RSI 9-day stood at 64.54%, suggesting the stock is Neutral, with a 52.16% historical volatility rate.
The stochastic %K and %D were 91.91% and 82.54% respectively, while the average true range (ATR) was 0.34. Based on the 14-day stochastic reading of 90.51%, the RSI (14) reading is 57.35%. On the 9-day MACD Oscillator, the stock is at 0.40, and the 14-day reading is at 0.45.
Atara Biotherapeutics Inc. (NASDAQ: ATRA) was downgraded by Citigroup to a a Sell rating in its latest research report. The stock was previously rated as a a Neutral. Analysts have assigned Atara Biotherapeutics Inc. (ATRA) an Overweight rating. ATRA is a stock that is recommended for selling by 2 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is ATRA’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.00 and $50.00, with a median target price of $14.65. In analyzing these forecasts, the average price target given by analysts for Atara Biotherapeutics Inc. (ATRA) is $18.79.